<DOC>
	<DOCNO>NCT01020799</DOCNO>
	<brief_summary>The purpose study prove principle treatment AZD7268 reduce depressive symptom patient Major Depressive Disorder ( MDD ) compare placebo .</brief_summary>
	<brief_title>AZD7268 Safety Tolerability Study</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Provision sign , write , date Informed Consent prior study specific procedure Documented primary clinical diagnosis meeting criterion DSMIV , Text Revision ( APA 2000 ) follow : 296.2x Major Depressive Disorder , Single Episode , 296.3x Major Depressive Disorder , Recurrent Patients secondary DSMIV Axis I disorder GAD social anxiety disorder ( assessed MINI ) , provide primary diagnosis MDD . This diagnosis make least 6 month enrollment Patients diagnosis DSMIV Axis II disorder major impact patient 's current psychiatric status Patients whose current episode depression start less 4 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Depression</keyword>
</DOC>